Raised CRP tracks with fracture — and should change nothing about how you assess risk

Design

PRISMA 2020 systematic review and random-effects meta-analysis, GRADE certainty assessment

Population

48 observational studies of serum, plasma or whole-blood inflammatory markers and fracture outcomes

Primary outcome

association between circulating inflammatory or immune markers and osteoporotic or fragility fracture

Effect

CRP and hip fracture 1.39 (95% CI 1.17 to 1.67); CRP and vertebral fracture 2.16 (1.47 to 3.18); TNF-related 1.81 (1.34 to 2.44); certainty low

A PRISMA-compliant systematic review and meta-analysis, registered in PROSPERO, searched five databases to June 2026 and pooled 48 observational studies on circulating inflammatory and immune markers against osteoporotic and fragility fracture outcomes, using random-effects models and GRADE.

CRP or high-sensitivity CRP exposures were associated with hip fracture (pooled ratio estimate 1.39, 95% CI 1.17 to 1.67) and more strongly with vertebral fracture (2.16, 1.47 to 3.18). Interleukin-6 was associated with hip fracture (1.40, 1.15 to 1.71), and TNF-alpha or soluble TNF receptors more so (1.81, 1.34 to 2.44). Blood-count-derived indices — neutrophil-lymphocyte ratios and the like — were unstable across studies. GRADE certainty was low throughout.

The authors draw the line themselves, and it is the right one: heterogeneity in design, timing, populations and whether bone mineral density was adjusted for means these associations cannot be read as causal or predictive, and the markers should not replace established fracture-risk assessment. What the work supports is the osteoimmune hypothesis as a research direction. It does not support adding a CRP to a fracture risk workup.

• Do not add inflammatory markers to fracture-risk assessment — keep using DXA and a validated risk tool
• Do not reassure a patient because their CRP is normal
• Note the association is strongest for TNF-related markers and vertebral fracture, both hypothesis-level
• In patients with chronic inflammatory disease, treat the disease activity as the fracture-relevant variable

Why it matters

It closes off a tempting shortcut — the inflammatory marker you already have does not measure fracture risk.

Don't overread it

These are observational associations at low certainty; they cannot show that inflammation causes fracture or that lowering a marker prevents one.

The statistics, in plain English

A pooled ratio of 1.39 from observational studies at low GRADE certainty means the association is consistent but the studies cannot separate inflammation from the frailty, comorbidity and immobility that travel with it. Several studies could not establish that the marker was measured before the fracture, which makes even the direction of the relationship uncertain.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.